J Neurol. 2026 May 15;273(6):314. doi: 10.1007/s00415-026-13846-6.
ABSTRACT
OBJECTIVE: Estrogen-containing oral contraceptives (OCPs) increase the risk of thromboembolic events including cerebral venous sinus thromboses (CVSTs). However, robust pharmacovigilance data comparing CVST risk across OCPs remain limited.
STUDY DESIGN: The FDA Adverse Event Reporting System (FAERS) was used to investigate which OCPs are associated with a disproportionally high CVST reporting.
RESULTS: There were 479 reports of CVST across OCPs. Estrogen containing contraceptives were associated with disproportionally high CVST reporting, with ethinyl estradiol + drosperinone exhibiting the most substantial association (reporting odds ratio: 38.1, 345 cases).
CONCLUSION: Clinicians should educate those taking estrogen-containing OCPs on how to identify CVST symptoms.
PMID:42141300 | DOI:10.1007/s00415-026-13846-6